Licencing Opportunity:
This work represents a licensing opportunity.
1) Preparation of macrophage activating factor, GcMAF. (US/Europe/Canada/Japan/Norway/Russia/China) 2)Diagnostic/prognostic tumor-specific enzyme assay (US)
Further Information:
Macrophages activated by GcMAF are highly tumoricidal and eradicate a variety of cancers indiscriminately and also HIV but produce no side effects in humans.
Related Industry Reports:
- Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
- Pipeline Insight: Breast Cancer - Targeted Therapies, New Cytotoxics and Vaccines
- Pipeline Insight: Breast Cancer - Complex Combinations of Old and New?
- Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline
- Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
International journal of cancer. Journal international du cancer 2007 Oct 12; 122(2):461-7
Yamamoto N, Suyama H, Yamamoto N, Ushijima N
Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126‐3305.
Serum vitamin D(3)-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized beta-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years. (c) 2007 Wiley-Liss, Inc.
Keywords: breast cancer Immunotherapy